Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several adverse effects and some safety concepts are supported by the provided label excerpts (e.g., headache, nausea/vomiting, diarrhea, renal failure/renal dysfunction, hepatic lab abnormalities). However, multiple claims about specific forms of acyclovir, specific neurotoxicity manifestations, increased risk statements, “other infection” risk, and references to specific journals/studies and monitoring recommendations are not supported by the supplied label text.
Category Scores
Accurate Statements
Acyclovir can cause headache.
ADVERSE REACTIONS (Observed During clinical practice): 'headache' listed under General; and Long-Term Administration control patients reported 'headache (2.2%)'.
Acyclovir can cause nausea and vomiting.
ADVERSE REACTIONS (Short-Term Administration): 'nausea and/or vomiting' reported; also Observed During Clinical Practice includes 'nausea'.
Acyclovir can cause diarrhea.
ADVERSE REACTIONS (Long-Term Administration): diarrhea reported; and Chickenpox trials: 'diarrhea (3.2%)'. Also Observed During clinical practice includes 'Diarrhea'.
Acyclovir can cause kidney damage.
WARNINGS: 'Renal failure, in some cases resulting in death, has been observed with acyclovir therapy.' ADVERSE REACTIONS (Observed During clinical practice): 'Renal failure' and related renal findings.
Acyclovir-associated kidney damage may be more likely in people with pre-existing kidney problems.
PRECAUTIONS: 'Dosage adjustment is recommended when administering acyclovir to patients with renal impairment.' and 'Caution... may increase the risk of renal dysfunction...' (supports increased risk in renal impairment context).
Acyclovir has been reported to cause hepatotoxicity (liver damage), although this is rare.
ADVERSE REACTIONS (Observed During clinical practice): 'Elevated liver function tests, hepatitis, ... jaundice.' Label excerpt does not explicitly quantify rarity, but supports liver injury events being reported.
Unsupported Statements
Acyclovir inhibits replication of HSV and VZV viruses.
No mechanism-of-action statement is present in the provided label excerpts.
Acyclovir is available in oral, topical, and injectable forms.
The provided label excerpts mention oral and intravenous administration; 'topical' dosage form is not supported in the supplied text.
Acyclovir is used to treat cold sores, genital herpes, and shingles.
The label provided includes genital herpes and herpes zoster (shingles), but does not mention 'cold sores' as an indication in the supplied INDICATIONS AND USAGE text.
Acyclovir can cause fatigue.
No 'fatigue' term appears in the provided adverse reactions excerpts (though 'malaise' is listed).
Prolonged use of acyclovir has been linked to neurotoxicity.
The provided label excerpts include central nervous system symptoms and encephalopathy-type terms in post-approval use, but do not state that 'prolonged use' is linked to neurotoxicity.
Neurotoxicity from prolonged acyclovir use can cause numbness, tingling, or burning sensations in the hands and feet.
The label excerpts list CNS symptoms (e.g., paresthesia) but do not specifically describe numbness/tingling/burning in the hands and feet nor connect them to neurotoxicity from prolonged use.
Acyclovir has been reported to cause hepatotoxicity (liver damage), although this is rare.
The provided label excerpt reports liver-related events but does not state they are 'rare.'
Long-term use of acyclovir may increase the risk of developing other infections such as bacterial or fungal infections.
No such risk is mentioned in the provided label excerpts.
A study in the Journal of Antimicrobial Chemotherapy found that prolonged use of acyclovir was associated with an increased risk of neurotoxicity.
No study citations or journal names are present in the supplied label excerpts.
A study in the Journal of Infectious Diseases found that acyclovir use was linked to an increased risk of kidney damage in people with pre-existing kidney problems.
No study citations or journal names are present in the supplied label excerpts.
Regular monitoring of kidney function and liver enzymes can help identify potential issues early in people using acyclovir regularly.
The provided label excerpts do not include a monitoring recommendation for kidney function or liver enzymes.
Prolonged use of acyclovir has been linked to potential long-term risks including neurotoxicity, kidney damage, and hepatotoxicity.
While renal failure and neuro/CNS adverse events and liver-related events are listed, the provided excerpts do not link these specifically to 'prolonged use' nor describe them as 'long-term risks' tied to duration.
Acyclovir is generally recommended to be used for the shortest duration necessary to manage symptoms and reduce the risk of long-term side effects.
The provided label excerpts include specific durations by indication, but do not state a general recommendation to use the shortest duration necessary to reduce long-term side effects.
Contradictions
Important Omissions
No contraindications were evaluated because none were provided in the prompt label excerpts.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Several safety claims are partially supported (headache, nausea/vomiting, diarrhea, renal failure; CNS/liver events are present in post-approval lists), but multiple key statements are unsupported (topical availability, 'cold sores' indication, fatigue, detailed neurotoxicity symptom description, 'prolonged use' linkage, additional infection risk, journal-study assertions, and monitoring recommendations). Unsupported specifics could mislead interpretation of risk and management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts, particularly those asserting topical availability, 'cold sores' as an indication, prolonged-use linkage to neurotoxicity with specific symptom distribution, increased risk of other infections, journal-study findings, and monitoring recommendations.
Suggested Improvement
Restrict claims to the provided label text: use the listed indications (herpes zoster and genital herpes; chickenpox), cite supported adverse events (headache; nausea/vomiting; diarrhea; malaise; post-approval CNS/liver/renal events), and avoid adding unsupported details (topical form, 'cold sores', specific paresthesia distribution from prolonged use, additional infection risk, journal citations) unless present in the supplied label.